Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer.

摘要: With the successful identification of many tumor-specific antigens, tumor-associated and potential using unfractioned tumor cell derivatives as a system and/or adjuvant that can deliver these antigens help them to induce strong effective anti-tumor immune responses is greatly needed. Previously, we reported MHC class I-restricted peptide epitope derived from human papillomavirus (HPV) 16 E7 protein, when incorporated into clinically proven safe LPD (liposome-polycation-DNA) particle, was able effectively eradicate tumors established in mice. Cervical cancer second most common among women worldwide. HPV infection clearly linked this cancer. Vaccines based on early (E) gene products could be controlling it. However, besides fact vaccines have limitations particularly, concerning diverse HLAs humans, use an antigen prevented us fully characterizing induced by vaccine carrier previous studies. In present study, protein antigen, first showed LPD, robust responses, both cellular antibody. We then immunization with particles either wild type or potentially safer mutant caused complete regressions model cervical murines. potent for antigens.